Literature DB >> 9921808

Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations.

L Garderet1, V Snell, D Przepiorka, T Schenk, J G Lu, F Marini, E Gluckman, M Andreeff, R E Champlin.   

Abstract

BACKGROUND: T cells present in an allogeneic bone marrow transplant may produce graft-versus-host disease but also contribute to immune reconstitution and enhance engraftment. Our aim was to separate alloreactive from nonalloreactive T lymphocytes, by performing a mixed lymphocyte culture (MLC) stimulation of donor cells, followed by selective depletion of activated cells expressing the high-affinity interleukin 2 receptor. We then characterized the resulting depleted cell fraction.
METHODS: Donor peripheral blood mononuclear cells were cocultured with irradiated peripheral blood mononuclear cells from HLA-nonidentical recipient stimulators in an MLC. After 3 days, CD25+ lymphocytes (alloreactive cells expressing the alpha chain of the interleukin 2 receptor) were removed by immunomagnetic separation. The depleted donor fraction and untreated cells were then rechallenged in a secondary MLC with the original irradiated stimulator cells or a third party to assess relative alloreactivity.
RESULTS: Inhibition of the secondary MLC and of host-specific cytotoxic activities was observed as well as a disappearance of interleukin 2 receptor-positive cells. Alloreactivity against unrelated third-party cells was preserved. Limiting dilution analysis of residual alloantigen-reactive T lymphocytes demonstrated a 1.3 log reduction of antihost reactivity. The depletion largely removed host-specific alloreactive CD4+ cells.
CONCLUSIONS: This method reduces alloreactivity while retaining reactivity against third-party targets. This approach may allow therapeutic infusion of T cells after HLA-nonidentical allografts with a reduced capacity to produce graft-versus-host disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9921808     DOI: 10.1097/00007890-199901150-00021

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

2.  Quantification of non-specific binding of magnetic micro- and nanoparticles using cell tracking velocimetry: Implication for magnetic cell separation and detection.

Authors:  J J Chalmers; Y Xiong; X Jin; M Shao; X Tong; S Farag; M Zborowski
Journal:  Biotechnol Bioeng       Date:  2010-04-15       Impact factor: 4.530

3.  Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.

Authors:  Osnat Bohana-Kashtan; Sebastien Morisot; Richard Hildreth; Cory Brayton; Hyam I Levitsky; Curt I Civin
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

4.  Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation.

Authors:  Thea M Friedman; Kira Goldgirsh; Stephanie A Berger; Jenny Zilberberg; Joanne Filicko-O'Hara; Neal Flomenberg; Michele Donato; Scott D Rowley; Robert Korngold
Journal:  Blood       Date:  2008-06-09       Impact factor: 22.113

5.  The role of peptides in T cell alloreactivity is determined by self-major histocompatibility complex molecules.

Authors:  R Obst; N Netuschil; K Klopfer; S Stevanović; H G Rammensee
Journal:  J Exp Med       Date:  2000-03-06       Impact factor: 14.307

6.  Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis.

Authors:  Denis Claude Roy; Sylvie Lachance; Sandra Cohen; Jean-Sébastien Delisle; Thomas Kiss; Guy Sauvageau; Lambert Busque; Imran Ahmad; Lea Bernard; Nadia Bambace; Radia S Boumédine; Marie-Claude Guertin; Katayoun Rezvani; Stephan Mielke; Claude Perreault; Jean Roy
Journal:  Br J Haematol       Date:  2019-05-28       Impact factor: 6.998

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.